DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Wednesday.

Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, April 6th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a research report on Thursday, June 1st. Societe Generale raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, March 16th. Leerink Swann reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, March 15th. Finally, Natixis raised DBV Technologies from a “neutral” rating to a “buy” rating in a research report on Friday, February 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $46.50.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Shares of DBV Technologies (DBVT) traded down 0.67% on Wednesday, reaching $32.74. The company’s stock had a trading volume of 49,556 shares. DBV Technologies has a 52-week low of $27.02 and a 52-week high of $37.98. The company’s market cap is $1.51 billion. The stock has a 50-day moving average of $34.33 and a 200 day moving average of $34.82.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades DBV Technologies S.A. (DBVT) to Strong Sell” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/14/bidaskclub-downgrades-dbv-technologies-s-a-dbvt-to-strong-sell.html.

Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its stake in shares of DBV Technologies by 3.1% in the first quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock worth $1,955,000 after buying an additional 1,647 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of DBV Technologies during the first quarter worth about $1,120,000. Jane Street Group LLC purchased a new stake in shares of DBV Technologies during the first quarter worth about $853,000. Bank of America Corp DE raised its stake in shares of DBV Technologies by 86.3% in the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock worth $936,000 after buying an additional 12,309 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares during the last quarter. 48.23% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.